Sub-Navigation

• Investor News
• Ad-hoc Publications
• Press
• Archive
  • Overview
  • Investor News 2011
  • Investor News 2010
  • Investor News 2009
  • Investor News 2008
  • Investor News 2007
  • Investor News 2006
  • Investor News 2005
  • Investor News 2004
  • Investor News 2003
  • Investor News 2002
  • Investor News 2001
  • Investor News 2000
  • Ad-hoc 2011
  • Ad-hoc 2010
  • Ad-hoc 2009
  • Ad-hoc 2008
  • Ad-hoc 2007
  • Ad-hoc 2006
  • Ad-hoc 2005
  • Ad-hoc 2004
  • Ad-hoc 2003
  • Ad-hoc 2002
  • Ad-hoc 2001
  • Ad-hoc 2000
  • Ad-hoc 1999
  • Ad-hoc 1998

Bayer Links

• Bayer Global
• Sustainability
• Press
• Bayer in Social Media

Additionals

• General Conditions of Use
• Privacy Statement
• Imprint
• Technical Details

Klickpfad

• Home
• News
• Archive
• Investor News 2006

Search

Here you find Investor News of year 2006. Ad-hoc messages issued in year 2006 can be found here.

Publications of the previous years are offered in the Archive Overview.

To view the PDF documents you will need the Acrobat Reader. Please click here to download the free Adobe Acrobat Reader software.

Receive our IR News via E-Mail, RSS Feed or SMS.

Monday December 18, 2006

Dow to Acquire Wolff Walsrode from Bayer

Acquisition underscores Dow's commitment to Performance businesses / Will create US Dollar 1 billion Water Soluble Polymers business for Dow

Friday December 15, 2006

Two acquisitions advance Bayer CropScience U.S. cotton platform

Assets of CPCSD and Reliance Genetics strengthen growing cotton seed portfolio

Monday December 11, 2006

Bayer and Nuvelo announce Phase 3 trials of alfimeprase in Patients with acute peripheral arterial occlusion and catheter occlusion did not meet primary endpoint

Monday December 04, 2006

Phase III Trial of Nexavar in Patients with Advanced Melanoma Does Not Meet Primary Endpoint

Monday November 27, 2006

Fall Financial News Conference 2006 of Bayer AG

Wenning: Schering acquisition provides additional boost to Bayer

Third-quarter sales up 26.0 percent to EUR 7,783 million / EBITDA before special items up 38.5 percent to EUR 1,505 million / EBIT before special items up 22.2 percent to EUR 798 million / Bayer aims to significantly improve underlying EBIT and EBITDA in 2006 / HealthCare earnings forecast raised

Thursday November 23, 2006

Auction process successfully concluded:

Bayer sells H.C. Starck to Advent International and The Carlyle Group for EUR 1.2 billion

Proceeds will help to finance the Schering acquisition / Acquirers plan expansion of H.C. Starck business / Goal is to position the company for an initial public offering in 3 to 5 years

Thursday November 09, 2006

Further integration measures determined:

Global R&D organization for future Bayer Schering Pharma defined

Global R&D units in Berlin and Wuppertal, Germany, and Berkeley, California / U.S. headquarters of Bayer Schering Pharma to be located in Wayne and Montville, New Jersey / Recommendations already made for some 70 Bayer Schering Pharma sites

Wednesday November 08, 2006

Patient Recruitment for Phase III Clinical Trial to Start in Studies of Oral Anticoagulant in Chronic Indications

Bayer and Ortho-McNeil, Inc. Outline Phase III Study Program of Oral Factor Xa Inhibitor Rivaroxaban in Chronic Indications

Phase III studies in chronic indications to involve more than 20,000 patients / Phase III trials to study stroke prevention in atrial fibrillation will begin patient recruitment during the coming weeks; phase III trials for the treatment of venous thromboembolism (VTE) will start recruiting in early 2007 / Based on the finalization of the study design, the companies are targeting a regulatory filing of rivaroxaban in these indications in 2010

Wednesday November 08, 2006

Acquisition progressing

Go-ahead for Schering's integration into the Bayer Group

EUR 89.36 cash compensation offer to Schering's outside stockholders

Tuesday October 31, 2006

Press Forum: Bayer's Perspective on Innovation 2006:

Wenning: “Research is the key to success”

Three new patent applications every working day help safeguard Bayer's future / Technology of the future: plant-made pharmaceuticals / Group-wide innovation initiative “Triple-i” successfully launched

Monday October 30, 2006

Entry in the commercial register

Agreement between Bayer and Schering in force

Resolution of Schering Extraordinary Stockholders' Meeting implemented

Wednesday October 25, 2006

Bayer HealthCare Acquires Western OTC Cough and Cold Business of Topsun Science and Technology

Monday October 23, 2006

Chemical park operator Bayer Industry Services presents new strategy:

Lower-cost services to strengthen competitive position of 60 Chemical Park partners

Savings of EUR 125 million / 600 jobs to be cut through 2009

Monday October 23, 2006

Bayer MaterialScience to acquire Taiwan's Ure-Tech Group

New global leader in thermoplastic polyurethane resins and films

Wednesday October 18, 2006

Bayer HealthCare and Regeneron to Collaborate on VEGF Trap for the Treatment of Eye Diseases

Regeneron Retains U.S. Commercialization Rights, Receives $75 Million Upfront, and Eligible for up to $245 Million of Milestone Payments

Tuesday October 17, 2006

Work to re-establish production progressing rapidly at Bayer MaterialScience TDI unit in Baytown

Wednesday October 11, 2006

Bayer MaterialScience closes MDI Facility at New Martinsville, W.Va., USA

Friday September 29, 2006

Bayer Acknowledges That New Trasylol Study Was Not Disclosed Prior to Recent FDA Cardio-Renal Advisory Committee Meeting

Friday September 29, 2006

Bayer MaterialScience: Costs of damage in Baytown not yet calculable

Production restricted following explosion in TDI plant

Company declares state of force majeure

Thursday September 21, 2006

FDA Advisory Committee Strongly Endorses Use of Trasylol in CABG Surgery Patients

Wednesday September 20, 2006

Bayer MaterialScience constructs world-scale plant for chlorine recycling

Innovative hydrochloric acid electrolysis in Shanghai

Oxygen-depleting cathode technology deployed on a large scale for the first time

Tuesday September 19, 2006

Bayer CropScience CEO Professor Dr. Friedrich Berschauer:

“We want to more intensively exploit the opportunities for growth in the areas of innovation, new technologies and seeds”

Plans to expand the seeds business to 15 % of total sales by 2015 / Annual research budget to increase to EUR 750 million over the same period

Monday September 18, 2006

Bayer MaterialScience raises sales prices for coating raw materials

Thursday September 14, 2006

Bayer divests holding in GE Bayer Silicones

49.9 percent interest sold to majority stockholder General Electric / Proceeds of EUR 475 million

Thursday September 14, 2006

Extraordinary Stockholders' Meeting of Schering AG

Stockholders pave the way for Bayer Schering Pharma

Schering Supervisory Board elects Werner Wenning as Chairman / Arthur Higgins named Management Board Chairman of the future Bayer Schering Pharma AG

Wednesday September 13, 2006

Extraordinary Stockholders' Meeting of Schering AG in Berlin

Erlen: Very good prospects for Bayer Schering Pharma

- Stockholders resolve on domination and profit and loss transfer agreement/ - New stockholders' representatives appointed to the Supervisory Board

Monday September 11, 2006

Bayer MaterialScience raises prices for polyurethane chemicals

Affected are the toluene diisocyanate (TDI) grades Desmodur® T80 and T65 as well as Desmophen® and Arcol® polyether polyols

Saturday September 09, 2006

Schering acquisition: Bayer reaches squeeze-out threshold

Tuesday September 05, 2006

World Congress of Cardiology 2006:

New phase II studies demonstrate that Factor Xa inhibitor rivaroxaban is a promising oral anticoagulant for chronic use

Largest Phase II dose-finding programme reported in this setting to date / Oral dosing without the need for monitoring might set a new standard for anticoagulation therapy

Tuesday September 05, 2006

Bayer CEO Wenning at the inauguration of new production facilities in Shanghai

“China is of central importance to Bayer”

Total capital expenditures of US$ 1.8 billion at the Shanghai Chemical Industry Park through 2009 / Significant capacity expansions for polycarbonates, polyurethanes and coating raw materials / Bayer's largest capital expenditure project outside Germany

Friday September 01, 2006

Bayer MaterialScience raises prices for Apec ®, Makrolon®, Bayblend® and Makroblend® polycarbonates

Wednesday August 30, 2006

Bayer CropScience to divest a limited number of crop protection products to United Phosphorus Limited

Company focusing on innovative higher-margin products

Tuesday August 29, 2006

Strong second quarter in 2006

Wenning: Continuing success for Bayer both strategically and operationally

Sales up 5.8 percent to EUR 7,072 million / EBITDA before special items advances 11.2 percent to EUR 1,342 million / EBIT before special items climbs 14.1 percent to EUR 928 million / Bayer Group targets improvement in underlying operating result for 2006 / New restructuring program launched at Bayer CropScience

Friday August 11, 2006

Innovative active ingredients to control fungal infections in cereals

Prothioconazole and fluoxastrobin receive marketing authorization in the important French market

Thursday August 10, 2006

Patrick W. Thomas named new Management Board Chairman of Bayer MaterialScience AG

Current Chairman Dr. Hagen Noerenberg to retire

Friday August 04, 2006

Extraordinary Stockholders' Meeting of Schering AG on September 13, 2006:

Schering's stockholders to resolve on domination and profit and loss transfer agreement with Bayer

Election of new investor representatives to the Supervisory Board/ - Renaming to “Bayer Schering Pharma Aktiengesellschaft”

Tuesday August 01, 2006

Bayer MaterialScience increases MDI production in Krefeld-Uerdingen

Global MDI production capacity exceeds one million tons

Efficient utilization of existing capacities through debottlenecking measures

Monday July 31, 2006

Following recent developments at Schering:

Bayer stands by compensation offer of EUR 89 per Schering AG share

Wednesday July 26, 2006

Bayer offers cash compensation of EUR 89 per Schering AG share

Sunday July 23, 2006

Nexavar® Approved by European Commission for the Treatment of Advanced Kidney Cancer

Wednesday July 12, 2006

Takeover offer completed

Bayer controls 92.4 percent of outstanding Schering shares

Goal remains to wholly acquire the Berlin pharmaceuticals company

Monday July 03, 2006

To finance Bayer's investment program in Caojing, China:

Bayer successfully syndicates a EUR 610 million equivalent credit facility in China

Long-term credit facility available in Renminbi or U.S. dollars/ Syndication significantly oversubscribed

Thursday June 29, 2006

Bayer Supervisory Board extends Werner Wenning's contract until 2010

Contracts of Management Board members Klaus Kühn and Dr. Richard Pott also renewed

Thursday June 29, 2006

HealthCare strategy being systematically implemented

Bayer to sell diagnostics business to Siemens for EUR 4.2 billion

Bayer Diabetes Care Division and Schering contrast agents business not affected / Decision not driven by financing of Schering acquisition

Tuesday June 27, 2006

Bayer CropScience acquires rights to FMC Corporation´s insecticides discovery pipeline

Successful innovation is a key driver for Bayer CropScience

Wednesday June 21, 2006

Company's biggest-ever transaction successful:

Bayer and Schering optimistic about their common future

Higgins to be Management Board Chairman of Bayer Schering Pharma AG / Köstlin, Rubin, Riemann and Baumann will join the Management Board / Wenning to become Supervisory Board Chairman of Bayer Schering Pharma AG / Erlen will be Supervisory Board Vice Chairman / Extraordinary Stockholders' Meeting of Schering AG in September

Tuesday June 20, 2006

Minimum acceptance threshold of 75 percent exceeded

Bayer: Takeover offer for Schering successful

Bayer now controls 88.0 percent of issued and outstanding Schering shares / Additional acceptance period will run from June 23 to July 6, 2006

Wednesday June 14, 2006

Pfizer Signs Agreement with Bayer to License Compounds for Potential Treatment of Obesity, Diabetes and Related Disorders

Wednesday June 14, 2006

Merck offers Bayer its stake in Schering

Successful acquisition of Schering by Bayer now much more likely / Wenning: “All three companies concerned will benefit from this step” / Suit filed against Merck to be withdrawn

Wednesday June 14, 2006

Bayer still aims to secure a majority holding in Schering

Wenning: “We're ready for the second round” / “Mandatory offer” to Schering stockholders in preparation / Suit for damages filed against Merck for violating U.S. capital market law

Tuesday June 13, 2006

Bayer considering further purchases of Schering shares outside of the takeover offer

Possibility of purchases above the EUR 86 offer price / Highest price paid would apply to all Schering shares tendered under the takeover offer / Acceptance period ends at midnight CEST Wednesday

Monday June 12, 2006

27th Goldman Sachs Annual Global Healthcare Conference

Bayer antithrombosis drug BAY 59-7939: Compelling data from recent phase II clinical studies support decision to proceed with phase III programs

Phase III programs in two chronic indications / Once-daily dosing in the phase III programs for stroke prevention in atrial fibrillation and treatment of venous thromboembolism

Friday June 09, 2006

Merck's actions in respect of Schering incomprehensible

Bayer now purchasing Schering stock on the market / Takeover offer remains valid

Monday June 05, 2006

Updated Overall Survival Analysis Presented on Nexavar Phase III Trial

Friday June 02, 2006

Largest stockholder accepts takeover offer

Allianz tenders its Schering shares to Bayer

Overall acceptance rate rises to 39.21 percent / Acceptance period ends on June 14, 2006 – no further extension possible

Tuesday May 30, 2006

Bayer amends takeover offer

Acceptance period for Schering stockholders extended by two weeks

Acceptance period now ends on June 14, 2006 / Further amendment to offer conditions not possible / Minimum acceptance threshold remains at 75%, offer price at EUR 86 per share

Wednesday May 24, 2006

Antitrust authorities approve Bayer's acquisition of Schering

/ Transaction cleared unconditionally by the E.U. Commission / Antitrust clearance in the United States already obtained / Acceptance period for Schering stockholders ends on May 31, 2006

Wednesday May 24, 2006

Promising Early Clinical Trials for Bayer's longer acting Kogenate® Product

Thursday May 18, 2006

Bayer bond issues successfully placed

Thursday May 11, 2006

Planned acquisition of Schering AG:

Bayer launches new bond issues to replace a further part of the bridge financing

Loan syndication successfully completed

Friday April 28, 2006

Werner Wenning at the Annual Stockholders' Meeting in Cologne:

Acquisition of Schering is the right step for Bayer

HealthCare business the primary growth engine / Very strong performance of 2005 continued in the first quarter of 2006

Friday April 28, 2006

Nexavar® Receives Positive Opinion from European Committee for Medicinal Products for Human Use

Renal Cell Carcinoma Approval Received in Mexico

Thursday April 27, 2006

Interim report for the first quarter of 2006:

Bayer achieves record earnings

Wenning: dynamic start strengthens our optimism for the full year / Sales up 11.8 percent to EUR 7,494 million / EBIT before special items reaches an all-time high of EUR 1,236 million / Record underlying EBITDA of EUR 1,680 million

Wednesday April 26, 2006

FDA Grants Orphan Drug Designation to Nexavar for the Treatment of Hepatocellular Carcinoma

Tuesday April 18, 2006

European Commission Grants Orphan Medicinal Product Designation to Nexavar for the Treatment of Hepatocellular Carcinoma

Thursday April 13, 2006

Bayer makes official takeover offer for Schering

Acceptance period for the offer of EUR 86 per share ends on May 31, 2006 / Wenning: Offer is a worthwhile one for Schering shareholders

Monday April 10, 2006

Acute peripheral arterial occlusion (PAO):

Bayer HealthCare and Nuvelo begin second pivotal phase III trial of alfimeprase

Thursday March 30, 2006

Overallotment option for Bayer Mandatory Convertible Bond fully exercised

Thursday March 30, 2006

Nexavar Approved in Switzerland for the Treatment of Patients with Advanced Kidney Cancer

First European Approval in New Class of Cancer Therapy

Wednesday March 29, 2006

Bayer – EUR 2 billion mandatory convertible bond successfully placed

Strong interest of capital market for subordinated mandatory convertible bond

Wednesday March 29, 2006

Bayer announces the launch of a EUR 2 billion mandatory convertible bond

Subordinated mandatory convertible bond due in June 2009 / Conversion into shares of Bayer AG

Thursday March 23, 2006

Bayer plans to acquire Schering and offers stockholders EUR 86 per share

Creating a health care heavyweight of international standing with attractive growth potential / Schering Board of Management welcomes Bayer offer / Berlin to be future headquarters of “Bayer-Schering Pharmaceuticals” with anticipated sales of more than EUR 9 billion / Bayer HealthCare raises target EBITDA margin from 23 to 25 percent / Sound funding through a combination of equity and debt financing and divestment of two Bayer MaterialScience subsidiariesw

Monday March 06, 2006

Spring Financial News Conference on March 6

Wenning: 2005 a very successful year for Bayer

Strong growth: sales increase by 17.6 percent to EUR 27,383 million / EBIT before special items climbs by 55.9 percent to EUR 3,300 million / Strong cash flow performance – return on capital at record level / Further improvement in the underlying operating result targeted for 2006 / 2006 off to a good start

Thursday March 02, 2006

Bayer proposes increasing dividend to EUR 0.95

Thomas de Win elected Vice Chairman of the Supervisory Board

Wednesday March 01, 2006

Bayer responds to report in “Capital” magazine

Monday February 27, 2006

Treatment of central venous catheter occlusion:

Bayer HealthCare and Nuvelo begin second pivotal phase III trial of lead product candidate, alfimeprase

Thursday February 16, 2006

Bayer and Onyx Initiate Phase III Non-Small Cell Lung Cancer Trial Studying

Nexavar (sorafenib) tablets in Combination with Two Chemotherapeutic Agents

Wednesday February 08, 2006

Bayer and Global Regulatory Authorities Evaluating Published Reports on Trasylol

Bayer will publish and mail letters to Health Care Professionals

Thursday January 26, 2006

Observational study

Bayer Clinical Trials on Trasylol Not Consistent with New England Journal of Medicine (NEJM) Study

Monday January 23, 2006

Treatment of acute peripheral arterial occlusion:

Nuvelo Product Candidate Alfimeprase Receives FDA Fast Track Status

Bayer HealthCare To Commercialize Alfimeprase in All Territories Outside the U.S.

Wednesday January 11, 2006

Bayer acquires Icon Genetics AG

Thursday January 05, 2006

Product Perfectly Complements Bayer´s Hematology and Cardiology Portfolio:

Bayer HealthCare and Nuvelo Enter Into Collaboration Agreement for Global Development and Commercialization of Alfimeprase

- Bayer HealthCare To Commercialize in All Territories Outside the U.S. / - Nuvelo Retains U.S. Commercialization Rights and Will Receive Milestone Payments of up to $385 million

Tuesday January 03, 2006

Strategic fit for Bayer´s pharma business:

Bayer HealthCare purchases Pritor business from GlaxoSmithKline

- Annual turnover of approximately EUR 65 million in Europe / - Innovative medication for the treatment of high blood pressure